A study of Thalidomide, Bendamustine, and Dexamethasone (BTD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failure defined as a GFR below 30 mls/min
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone; Thalidomide
- Indications Myeloma
- Focus Therapeutic Use
- Acronyms OPTIMAL
- Sponsors Janssen-Cilag
- 12 Jun 2016 Planned End Date changed from 1 Jan 2017 to 1 Apr 2018.
- 12 Jun 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 04 Nov 2015 Accrual to Date is 2% according to the United Kingdom Clinical Research Network record.